Cardiovascular Changes Research Articles

Comparative study of cardiovascular changes using echocardiography and bnp among hypertensive and normotensive pregnant women

Comparative study of cardiovascular changes using echocardiography and bnp among hypertensive and normotensive pregnant women

Perfusion and pulsatile pressure: their relationship with target organ damage in the African-PREDICT study

BackgroundHypertension is the leading risk factor for subclinical target-organ damage (TOD) and cardiovascular disease (CVD). Little is known about the relationship between different pressure measures and subclinical TOD, especially in young populations. We compared the strength of associations of subclinical TOD markers with perfusion and pulsatile pressure in young adults.MethodsA total of 1 187 young adults from the African-PREDICT study were included. Ambulatory mean arterial pressure (MAP) and pulse pressure (PP) was obtained. Markers of subclinical TOD were measured and included left ventricular mass index (LVMi), carotid intimamedia thickness (cIMT), carotidfemoral pulse wave velocity (cfPWV), central retinal arteriolar equivalent (CRAE) and albumin to creatinine ratio (ACR).ResultsMeasures of sub-clinical TOD (cIMT, cfPWV and CRAE), associated stronger with perfusion pressure (all p < 0.001) than pulsatile pressure in unadjusted models. Stronger associations were found between cfPWV (adjusted R2 = 0.26), CRAE (adjusted R2 = 0.12) and perfusion pressure (all p ≤ 0.001) than pulsatile pressure independent of several non-modifiable and modifiable risk factors.ConclusionsIn young, healthy adults, perfusion pressure is more strongly associated with subclinical TOD markers than pulsatile pressure. These findings contribute to the understanding of the development of early cardiovascular changes and may guide future intervention strategies.

Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials.

Menopause, defined by the cessation of menstrual cycles after 12 months of amenorrhea not due to other causes, is associated with significant hormonal changes, primarily a decrease in estrogen, androgen, and progesterone levels. This review delves into the effects of estrogen deficiency during the perimenopausal transition and postmenopause, integrating the findings of basic science with clinical trials. Here, we first outline the variation in endogenous estrogens before and after menopause, exploring both genomic and nongenomic actions of estrogen and its estrogen receptors throughout the body. Next, we detail the spectrum of menopausal symptoms, from acute vasomotor, urogenital, and psychological issues during perimenopause to chronic reproductive, cardiovascular, neurological, skeletal, dermatologic, immune, and digestive changes postmenopause. Finally, we evaluate the role of hormone therapy in alleviating these symptoms, weighing its benefits against known risks. Publicizing these findings and an accurate representation of the risks and benefits of estrogen replacement to our aging patients is fundamental to improving their care, quality, and even quantity of life.

Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI.

Pharmacologic blockade of neurohormonal pathways in patients with acute myocardial infarction (MI) can result in acute changes in biomarkers of kidney function. We evaluated the effect of sacubitril/valsartan versus ramipril on initial changes in serum creatinine and the association of these changes with longer-term outcomes among participants in PARADISE-MI. In this randomized, double-blind, active-controlled, event-driven trial, 5661 patients with an acute MI were assigned to receive sacubitril/valsartan or ramipril, with no run-in. The frequency of an initial pre-specified increase in serum creatinine (≥26.5 or ≥44 μmol/L) from baseline to week 1 was compared between arms. Multivariable Cox regression models were fit to examine the association of acute changes in serum creatinine with the primary cardiovascular composite outcome (cardiovascular death, first heart failure hospitalization, or outpatient heart failure), all-cause mortality, and longer-term changes in estimated glomerular filtration rate (eGFR). An initial increase in serum creatinine ≥26.5 μmol/L occurred in 155 of 2604 (6.0%) patients assigned to sacubitril/valsartan and 120 of 2603 (4.6%) patients assigned to ramipril (odds ratio [OR] 1.32; 95% confidence interval [CI] 1.03-1.68). The corresponding numbers for an increase ≥44 μmol/L were 57 (2.2%) and 42 (1.6%), respectively (OR 1.37; 95% CI 0.92-2.05). A higher odds of increased serum creatinine ≥26.5 and ≥44 μmol/L for sacubitril/valsartan versus ramipril appeared to be restricted to patients who had a greater decline in systolic blood pressure over the same period (p-interaction = 0.05 and 0.001, respectively). In multivariable analyses, neither an acute increase in serum creatinine ≥26.5 or ≥44 μmol/L was associated with a higher risk of cardiovascular outcomes, all-cause mortality, or differences in longer-term eGFR slope. Findings were similar across the randomized treatment arms (p-interaction >0.6 for all). Following acute MI, patients assigned to sacubitril/valsartan had a higher frequency of initial increases in serum creatinine at 1 week, compared with ramipril. In adjusted models, initial increases in serum creatinine with either treatment were not associated with adverse cardiovascular outcomes or changes in longer-term kidney function.

Normal M-mode, Pulsed Wave and Tissue Doppler Echocardiographic Studies in Healthy Working Police Dogs

Background: Physical activity alters the cardiovascular system of dogs depending on the exercise characteristics and the animal’s physical conditioning. Little is known about the cardiovascular changes in working police dogs. This study evaluated the cardiovascular responses of working Labradors to regular exercise and various workload. Methods: Twelve working Labradors of Tamil Nadu police department that were regularly trained and exercised 30 minutes morning and evening and twelve normal household pet Labradors brought for regular checkup to Madras Veterinary College Teaching hospital were taken for the study. All the animals were subjected to physical, clinical, hematobiochemical, electrocardiographic examinations and cardiac auscultation before performing echocardiography. Those animals which showed normal recordings in all the above tests were further subjected to M-mode, Pulsed wave and Tissue Doppler echocardiography. In this study, the resting heart rate values of working groups were lesser than that of normal pet dogs. Result: The results of echocardiography showed significant increase in Interventricular septal diameter during diastole, left atrial diameter, aortic artery diameter and the left atrium to aortic diameter ratio without impairing systolic and diastolic cardiac functions in working dogs. The present study indicated that there were few changes in the echocardiographic parameters which might be a response to physiological adaptation and regular exercise.

Impact of procedural handling on the physiological effects of alfaxalone anaesthesia in the ball python (Python regius)

To describe the cardiovascular changes following intramuscular (handled) and intravascular (undisturbed, via intraarterial catheter) alfaxalone administration, we studied 20 healthy ball pythons (Python regius) in a randomised, prospective study. The pythons were instrumented with occlusive arterial catheters to facilitate undisturbed, continuous monitoring of heart rate and blood pressure. Six pythons were administered intramuscular (IM) saline, followed by 20 mg/kg IM alfaxalone, and were manually restrained for both injections. Six pythons received intraarterial (IA) saline, followed by 10 mg/kg IA alfaxalone, and remained undisturbed for both injections. Arterial blood samples were taken at 0, 12 and 60 min post-injection, and heart rate and blood pressure were recorded for 60 min. The remaining eight snakes received 20 mg/kg IM or 10 mg/kg IA alfaxalone (n = 4 per treatment) and were not handled for intubation 10 min post-injection, to examine the effects of handling during anaesthesia. IM administration of 20 mg/kg alfaxalone or an equivalent volume of saline elicited a profound tachycardia and hypertension, which recovered to resting values after 20 min. However, when 10 mg/kg alfaxalone or saline were injected IA, mild hypotension and a lower magnitude tachycardia occurred. Arterial PCO2 and PO2, pH and lactate concentrations did not change following IA alfaxalone, but an acidosis was observed during IM alfaxalone anaesthesia. There were no significant changes in plasma catecholamines and corticosterone among treatments. Handling for injection and during anaesthesia associated with intubation significantly affects cardiovascular parameters, whereas alfaxalone per se only elicits minor changes in cardiovascular physiology.

Cardiovascular Changes in Individuals with Mood Disorders: A Comprehensive Review

Cardiovascular Changes in Individuals with Mood Disorders: A Comprehensive Review

Exposure to Noise or Music in Clinical Trials: A Scoping Review on Ethical and Methodological Considerations.

Use of noise or music in experimental human studies requires balancing the need to avoid subjecting participants to potentially harmful noise levels while still reaching levels that will produce a measurable change in the primary outcome. Several methodological and ethical aspects must be considered. This study aims to summarize ethical and methodological aspects, and reported outcomes, of previously published experimental paradigms using loud noise/music. Four databases (Medline, Central, Web of Science, and Scopus) and two trials registries (Clinicaltrials.gov and EU Clinical Trials) were searched. Extracted items had the details of author and year of publication, study design and purpose, population, setting timeline and material, selected battery test, and effect of noise/music on participants' hearing. Thirty-four studies were included. Exposure safety considerations were reported in five studies. Eleven studies assessing hearing loss used white or narrow-band noise [(NBN (0.5-4 kHz), up to 115 dBA, duration range: 3'-24 hours)], and 10 used pop music (up to 106 dBA, duration range: 10'-4 hours). Experimental setting varied significantly. Temporary thresholds shift (TTS) and reduction in distortion product otoacoustic emissions were found at 1-8 kHz, with maximum average TTS∼21.5 dB at 4 kHz after NBN and ∼11.5 dB at 6 kHz after music exposure. All participants recovered their hearing, except for one participant in one study. In the 13 non-hearing loss studies, no hearing testing was performed after exposure, but loud noise was associated with temporary stress, bradygastria, and cardiovascular changes. Noise-induced subjective stress may be higher for participants with tinnitus. Loud noise (100 dBA, 10') increased diastolic and mean blood pressure only in participants with hypertension. Experimental exposure paradigms can produce temporary changes to hearing without measurable long-term health consequences. Methodological and ethical aspects identified in this review should be considered for the development of future paradigms.

Comparison of Cardiovascular Changes Seen in Patients When Using Local Anesthesia with Adrenalin 1:80,000 vs Local Anesthesia with Adrenalin 1:2,00,000

ABSTRACT Aim: The aim of this study is to compare the efficacy with the use of 2% lignocaine with adrenalin with two different concentrations and also its effect on the cardiovascular system. Materials and Methods: 100 patients were taken for this study. 68 were Male &amp; 32 females. Extractions of mandibular bilateral teeth (Molars and Pre Molars).2% lignocaine with two different concentrations - one with 1:80000 and the other with 1:200000. Irrespective of the number of teeth extracted, inferior alveolar and lingual nerve blocks were administered (long buccal whenever necessary). Unilateral extractions were carried out in a single sitting and the other side was done on next visit. A single operator carried out all the cases. All the patients were given the same pre-operative and post-operative instructions. A total of 4ml solution was injected on each side. Results: Systolic blood pressure, pulse rate, onset of anesthesia, durationnof anesthesia and blood loss all the parameter were significant woth p value less tan 0.05. Conclusion: In accordance to our study, 2% lignocaine in 1:2,00,000 dilution of adrenaline can safely be used in minor oral surgical procedures, and is safe in hypertensive and cardiac patients as this dilution does not alter any haemodynamic parameters to a great extent.

Controlled ovarian stimulation leads to cardiovascular changes in patients undergoing in vitro fertilization

ObjectiveTo study hemodynamic changes along controlled ovarian stimulation in women undergoing in vitro fertilization. Study designProspective observational cohort study conducted at Mother and Child Department of University Hospital Federico II, in Naples, Italy, between April 2021 and July 2022. Sixty-eight infertile patients undergoing controlled ovarian stimulation with gonadotropin, antagonist protocol and a fresh embryo transfer were included. Haemodynamic assessment was carried out using UltraSonic Cardiac Output Monitor at baseline (T1), estradiol peak (T2), fresh embryo-transfer day (T3). To evaluate relationships between quantitative variables and groups a Student T test for independent data was assessed. One-way analysis of variance (ANOVA) was used to determine the differences between the means of three time points (T1, T2 and T3) for quantitative variables. A mixed-model analysis of variance (ANOVA) was used to determine the differences between groups, among time points (T1, T2 and T3). ResultsSixty-eight patients were included. Significant differences over the three time points have been observed for CO (f = 3.78 l/min; p = 0.025), SVI (f = 3.56 ml/m2;p = 0.013), and RSVI (f = 4.84 dscm-5 m2; p = 0.009). No significant differences in trends have been found between beta hCG positive and beta hCG negative groups. There were no significant differences in maternal hemodynamic parameters at time-point T3 between patients treated with hCG 10,000 UI and with Triptorelin. Patients considered at increased risk of hyperstimulation reported a significant increase in SVI at baseline (26.9 ± 9.0 mL/m2 vs 21.9 ± 7.0 mL/m2; p = 0.010). ConclusionAccording to the results of our study, during controlled ovarian stimulation with antagonist protocol, patients undergo significant changes in maternal cardiovascular parameters over a very short period.

ATRIAL CARDIOMYOPATHY AND STROKE PREVENTION - REVIEW

Atrial cardiomyopathy (ACM) represents a novel paradigm in cardiovascular medicine, encompassing structural and functional changes within the atria that contribute to adverse clinical outcomes, notably stroke. This review explores the multifaceted implications of ACM, particularly its relevance independent of atrial fibrillation (AF) and its potential applications in stroke prevention and management. Advancements in imaging modalities, notably speckle-tracking echocardiography, offer valuable insights into atrial remodeling and dysfunction, facilitating early detection of ACM. Markers such as P-wave terminal force, NT-proBNP levels, and left atrial dimensions serve as diagnostic indicators for ACM, aiding in risk stratification in individuals devoid of AF history. Ischemic strokes are one of the most common causes of cardiovascular morbidity and mortality. A significant proportion of patients with ischemic stroke are suspected of embolic stroke without a specific embolic source being found (ESUS). The most recent related clinical trials evaluated tailored anticoagulation strategies in ACM-associated stroke, signaling a shift beyond conventional AF management. In conclusion, ACM emerges as a pivotal concept in stroke prevention, offering opportunities for personalized interventions and refined risk stratification beyond AF.

Value of fetal echocardiographic examination in pregnancies complicated by preterm premature rupture of membranes.

Cardiopulmonary and infectious complications are more common in preterm newborns after preterm premature rupture of membranes (pPROM). Fetal echocardiography may be helpful in predicting neonatal condition. Our aim was to assess the cardiovascular changes in fetuses from pregnancies complicated by pPROM and possible utility in predicting the intrauterine or neonatal infection, and neonatal heart failure (HF). It was a prospective study enrolling 46 women with singleton pregnancies complicated by pPROM between 18+0 and 33+6 weeks of gestation and followed until delivery. 46 women with uncomplicated pregnancies served as a control group. Fetal echocardiographic examinations with the assessment of cardiac structure and function (including pulmonary circulation) were performed in all patients. Mean gestational age of pPROM patients was 26 weeks. Parameters suggesting impaired cardiac function in fetuses from pPROM were: higher right ventricle Tei index (0.48 vs. 0.42 p<0.001), lower blood flow velocity in Ao z-score (0.14 vs. 0.84 p=0.005), lower cardiovascular profile score (CVPS), higher rate of tricuspid regurgitation (18.2 % vs. 4.4 % p=0.04) and pericardial effusion (32.6 vs. 0 %). Intrauterine infection was diagnosed in 18 patients (39 %). 4 (8.7 %) newborns met the criteria of early onset sepsis (EOS). HF was diagnosed in 9 newborns. In fetal echocardiographic examination HF group had shorter mitral valve inflow time and higher left ventricle Tei index (0.58 vs. 0.49 p=0.007). Worse cardiac function was observed in fetuses from pPROM compared to fetuses from uncomplicated pregnancies.

Immediate effect of Kaki Mudra on pupillary light reflex among healthy individuals – A study protocol of a Randomized control trial

Abstract Background Kaki Mudra is a yogic gesture that involves nasikagara drishti focusing on the nose tip without the eyes blinking and pursing the lips, which form beaks during inhalation, and exhaling slowly through the nose. However, there is a lack of evidence on the impact of kaki mudra on cardiovascular changes and autonomic function using pupillary light reflex (PLR). Methods A randomized control study design will be adopted for this study with 80 healthy participants with more than 18 years of age, will be recruited. Subjects will be randomly divided into the study (n = 40) and control groups (n = 40). The study group will be advised to practice Kaki Mudra for 20 min, whereas the control group will be asked to relax in sitting posture for 20 min. Results The baseline and post-assessment will be immediately evaluated for all the individuals; five leads to ECG for heart rate variability (HRV) and dynamic pupillometry for PLR. Discussion The immediate effect of kaki mudra is an effective and simple technique that might improve HRV and PLR variable, which may improve overall health and enhance parasympathetic dominance among healthy participants. The study is prospectively registered in the Clinical Trial Registry of India (CTRI/2024/05/067289).

Cardiovascular and haemodynamic changes in resistant hypertension: relation to blood pressure control in a longitudinal study

Cardiovascular and haemodynamic changes in resistant hypertension: relation to blood pressure control in a longitudinal study

Peripartum Cardiomyopathy

(N Engl J Med. 2024;390:154–164) Pregnancy induces cardiovascular physiological changes and can sometimes lead to severe complications. Severe cardiac degeneration leading to clinical heart failure during pregnancy or in the early postpartum period defines peripartum cardiomyopathy (PPCM), but little is known about its causes. This condition occurs in ∼1 in 2000 births globally, with more common diagnoses in Haiti (1 in 300) and Nigeria (1 in 100), and less commonly in other areas. Peripartum cardiomyopathy is a leading cause of maternal death and is responsible for up to 60% of cases of peripartum cardiogenic shock. This article is a review of what is known about PPCM, its clinical presentation, pathogenesis, management, outcomes, and future directions for research.

#2158 Circulating kidney injury molecule-1 a valuable marker of mortality in hemodialysis patients?

Abstract Background and Aims The importance of finding reliable biomarkers of mortality in CKD, and especially in patients treated with hemodialysis has become evident. Plasma KIM-1 has been mentioned as a marker of cardiovascular morbidity.. The aim of this study is to assess the level of plasma Kidney Injury Molecule- 1 (KIM-1) as a marker of mortality in patients treated with hemodialysis. Method We conducted a single-center study that included 63 CKD G5D patients (hemodialysis for 1-5 years) followed up for 48 months and a control group consisting of 52 patients diagnosed with CKD stages G1-G5, without HfrEF. All patients have been assessed at baseline, regarding cardiovascular disease (medical history, echocardiography and ECG). Circulating plasma KIM-1 levels were determined with single molecule counting immunoassay technology using the Enzyme-linked immunosorbent assay, we performed using standard methods blood biochemistry, and markers of inflammation (CRP, IL-6) and markers of anemia (complete blood count, serum ferritin, transferrin saturation- TSAT). Results Mean plasma KIM1 levels were 403.8 +/-546.8pg/ml) in the group of patients treated with hemodialysis, and was statistically significantly higher compared to the level in the control group (217.48 +/-267.10 pg/ml). In the group of patients treated with hemodialysis plasma KIM-1 levels showed a statistically significant correlation with inflammation (mean CRP- R=0.28, p=0.02 and IL6- R=0.36, p=0.005) and with anemia (hematocrit- R= -0.5, p=-0,0316; hemoglobin - R= -0.5, p=0.02 We found out using ANOVA that patients which presented left ventricular hypertrophy on echocardiography (37 out of 62) had significantly lower mean levels of plasma KIM-1 (155,51 vs 432,12 pg/ml; p=0,026). The group of patients with vascular calcifications on echocardiography (48 out of 62) had lower levels of serum KIM1 (210.01 vs 462.58 pg/ml, p=0.04). After 24 months of follow up we found a mortality rate of 22.23%, while after 48 months the mortality rate was of 50.73%. Using a Cox proportion-hazards regression analysis of predicting factors of mortality we found that regarding the relationship between plasma levels of KIM-1 and mortality there is a significantly decreased survival in patients with low KIM-1&amp;lt;81.98 pg/ml (p&amp;lt;0.001), with a cut-off point for plasma KIM-1 levels= 81.98 pg/ml. Conclusion Plasma KIM-1 levels were significantly higher in patients treated with hemodialysis compared to the control group (ND CKD patients). However, surprisingly, low levels of plasma KIM1 were associated with some cardiovascular changes and also to an increased risk of mortality (at 4 years, not after few months).

#2246 Cardiovascular changes and outcomes across the early CKD spectrum: a UK Biobank cardiovascular MRI substudy

Abstract Background and Aims Chronic kidney disease (CKD) patients are at a significant risk of accelerated cardiovascular (CV) disease (CVD), which increases as glomerular filtration rate (GFR) declines. The prevalence of CVD in early CKD is high but there is lack of data on early myocardial changes in this group of patients. We investigated the associations of early CKD with alterations in cardiac structure and function and adverse CV outcomes using cardiovascular magnetic resonance (CMR) imaging. Method We used measures of CMR analysis from participants in the UK Biobank CMR imaging substudy to extract information on morphology and function of the four heart chambers. Early CKD was defined as an estimated GFR with cystatin (eGFRcys) between 60 and 90 ml/min. Patients with left ventricular ejection fraction &amp;lt;50%, history of CVD, eGFRcys &amp;lt; 60 ml/min, uACR &amp;gt; 3 mg/mmol, and those on renal replacement therapy were excluded. The association between early CKD and CMR parameters was analysed in 5 linear regression models: unadjusted, age adjusted, sociodemographic adjusted, sociodemographic and lifestyle adjusted, and a fully adjusted model also including clinical characteristics. Cox regression analyses were used to determine association between mildly decreased eGFR and adverse CV outcomes (myocardial infarction, stroke, CV death, and a composite CV outcome). Results A total of 33 124 individuals [17 825 (53.8%) women, age 64 (11) years] who received CMR imaging between 2014 and 2019 and fulfilled the inclusion criteria were identified: 19,919 with no CKD and 13,205 with early CKD. Participants with early CKD were more likely to be older, males and smokers. In the fully adjusted model, early CKD was associated with structural changes in the left ventricle (LV) [mass −1.04 g (−1.75 to −0.33), end-diastolic volume −2.69 mL (−4.01 to −1.38), end-systolic volume −0.95 mL (−1.30 to −0.60)], right ventricle (RV) [end-diastolic volume −3.24 mL (−4.67 to −1.82), end-systolic volume −1.73 mL (−2.55 to −0.91)], right atrium (maximum volume −2.81 mL (−4.09 to −1.53), minimal volume −1.46 mL (−2.30 to −0.62)]. Early CKD was also associated with a change in LV global circumference strain [-0.16 (−0.31 to −0.01)] but it was not associated with changes in the left atrium parameters or functional parameters [LV ejection fraction 0.21 (−0.05 to 0.48), RV ejection fraction 0.21 (−0.07 to 0.49)]. These changes were not associated with adverse CV outcomes on multivariable analyses (HR for MI 1.35, 95% CI 0.94-1.94; HR for stroke 0.98, 95% CI 0.63-1.50). Conclusion In a low-risk general population (without known CVD and with preserved LV ejection fraction) mildly reduced kidney function, as measured with eGFRcys, was associated with smaller LV and RV volumes, larger LV mass, and impaired LV global circumference strain. This early cardiac remodelling was not associated with adverse CV outcomes, but the event rate was very small during follow up. These findings suggest that cardiomyopathy associated with early CKD is not a regional condition of the left ventricle but affects the heart globally.

#1182 Arterial hypertension and chronic obstructive pulmonary disease—problems of choice of therapy

Abstract Background and Aims The development of hypertension in COPD is based on the early formation of endothelial dysfunction in the small and large circulatory circles, increased sympathetic activity with an imbalance in the synthesis of catecholamines, a violation of the role of the lungs in the metabolism of vasoactive substances, oxidative stress, chronic systemic inflammation, an imbalance in the renin-angiotensin-aldosterone system (RAAS). There are few studies confirming the role of RAAS components in the pathogenesis of cardiovascular changes in patients COPD. The activity of angiotensin converting enzyme (ACE) increases with hypoxia, which may play an important role in increasing the degree of systemic hypertension. An increase in the function of the RAAS is possible both under the direct influence of hypoxia and indirectly through activation of the sympathoadrenal system. To evaluate the efficacy and tolerability of the angiotensin II receptor antagonist valsartan (Nortivan) at a dose 80-160 mg per day in patients with hypertension of 1-2 degrees and COPD of stage II-IV. Method The study design is a local, open, incomparable study on the efficacy and safety of the drug Nortivan in patients with hypertension in combination with COPD. We examined 18 patients with stage II-IV in remission, suffering from grade I and II hypertension, determined in accordance with the generally accepted classification of blood pressure levels (VNOK, 2010). Results The criteria for exclusion from the study were the presence in patients of complications of hypertension, coronary heart disease, decompensated chronic pulmonary heart, endocrine diseases requiring drug correction, kidney pathology, chronic heart failure, oral steroid therapy. 10 days in the last 6 months before inclusion in the study, oncological diseases and any other conditions that could interfere with the interpretation and evaluation of the results of the study. Patients who had not previously received antihypertensive treatment were included in the study immediately, and the rest underwent a washing period for 2 weeks. Patients received Nortivan as antihypertensive therapy for 24 weeks. The effectiveness of therapy was controlled by daily monitoring blood pressure. The choice of quality criteria for the effectiveness of therapy parameters SMAD is associated with literature data and own observations on the prevalence of diurnal blood pressure profiles in patients with hypertension and COPD with no decrease or increase in blood pressure at night, when office blood pressure figures are to a lesser extent reflect the effectiveness of antihypertensive therapy. The initial dosage was 80 mg/day. With insufficient hypotensive effect, the dose of the drug was doubled at the 4th week of treatment. The basic COPD therapy did not change throughout the study period and included anticholinergic drugs (ipratropium bromide, tiotropium bromide), beta2-adrenomimetic (fe-noterol) or a combination thereof. Initially and after 24 weeks of treatment, a complete laboratory examination was performed: a clinical blood test, a biochemical blood test. The thickness of the intima-media complex of the carotid arteries and ECG was also studied. The criterion The safety of the therapy was assessed by the indicators of respiratory function, daily pulse oximetry. Conclusion The use of the drug Nortivan has shown high efficacy and safety in patients Grade I–II hypertension in combination with stage II-IV COPD. A statistically and clinically significant normalization of SMAD indicators with correction of pathological types of daily curves due to a decrease in the number of patients with an increase in or the absence of a decrease in blood pressure during the night period. The safety of using the drug in the clinical group with bronchial obstruction syndrome was confirmed by the dynamics of ventilation indicators according to spirometry and the results of daily pulse oximetry, which showed the absence of exacerbation of hypoxia during therapy.

Guidelines for assessing maternal cardiovascular physiology during pregnancy and postpartum.

Maternal mortality rates are at an all-time high across the world and are set to increase in subsequent years. Cardiovascular disease is the leading cause of death during pregnancy and postpartum, especially in the United States. Therefore, understanding the physiological changes in the cardiovascular system during normal pregnancy is necessary to understand disease-related pathology. Significant systemic and cardiovascular physiological changes occur during pregnancy that are essential for supporting the maternal-fetal dyad. The physiological impact of pregnancy on the cardiovascular system has been examined in both experimental animal models and in humans. However, there is a continued need in this field of study to provide increased rigor and reproducibility. Therefore, these guidelines aim to provide information regarding best practices and recommendations to accurately and rigorously measure cardiovascular physiology during normal and cardiovascular disease-complicated pregnancies in human and animal models.

Symptom-to-balloon time and risk of ventricular arrhythmias in patients with STEMI undergoing percutaneous coronary intervention: The VERY-STEMI study

BackgroundVentricular arrhythmias (VAs) mainly occur in the early post-myocardial infarction (MI) period. However, studies examining the association between total myocardial ischemia time interval and the risk of new-onset VAs during a long-term follow-up are scarce. MethodsThis study (symptom-to-balloon time and VEntricular aRrhYthmias in patients with STEMI, VERY-STEMI study) was a multicenter, observational cohort and real-world study, which included patients with ST-segment elevation MI (STEMI) undergoing percutaneous coronary intervention (PCI). The primary endpoint was cumulative new-onset VAs during follow-up. The secondary endpoints were the major adverse cardiovascular events (MACE) and changes in left ventricular ejection fraction (ΔLVEF, %). ResultsA total of 517 patients with STEMI were included and 236 primary endpoint events occurred. After multivariable adjustments, compared to patients with S2BT of 24 h-7d, those with S2BT ≤ 24 h and S2BT > 7d had a lower risk of primary endpoint. RCS showed an inverted U-shaped relationship between S2BT and the primary endpoint, with an S2BT of 68.4 h at the inflection point. Patients with S2BT ≤ 24 h were associated with a lower risk of MACE and a 4.44 increase in LVEF, while there was no significant difference in MACE and LVEF change between the S2BT > 7d group and S2BT of 24 h-7d group. ConclusionsS2BT of 24 h-7d in STEMI patients was associated with a higher risk of VAs during follow-up. There was an inverted U-shaped relationship between S2BT and VAs, with the highest risk at an S2BT of 68.4 h.